194 related articles for article (PubMed ID: 33962676)
1. Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice.
Furihata T; Maekawa S; Takada S; Kakutani N; Nambu H; Shirakawa R; Yokota T; Kinugawa S
BMC Pharmacol Toxicol; 2021 May; 22(1):27. PubMed ID: 33962676
[TBL] [Abstract][Full Text] [Related]
2. Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins.
Nagiub M; Filippone S; Durrant D; Das A; Kukreja RC
Can J Physiol Pharmacol; 2017 Mar; 95(3):295-304. PubMed ID: 28238269
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy.
Li L; Takemura G; Li Y; Miyata S; Esaki M; Okada H; Kanamori H; Ogino A; Maruyama R; Nakagawa M; Minatoguchi S; Fujiwara T; Fujiwara H
Lab Invest; 2007 May; 87(5):440-55. PubMed ID: 17334414
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin prevents doxorubicin-induced myocardial dysfunction.
Sabatino J; De Rosa S; Tammè L; Iaconetti C; Sorrentino S; Polimeni A; Mignogna C; Amorosi A; Spaccarotella C; Yasuda M; Indolfi C
Cardiovasc Diabetol; 2020 May; 19(1):66. PubMed ID: 32414364
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of tadalafil on left ventricular dysfunction in doxorubicin-induced cardiomyopathy.
Jin Z; Zhang J; Zhi H; Hong B; Zhang S; Guo H; Li L
J Cardiol; 2013 Aug; 62(2):110-6. PubMed ID: 23731918
[TBL] [Abstract][Full Text] [Related]
7. Loss of multidrug resistance-associated protein 1 potentiates chronic doxorubicin-induced cardiac dysfunction in mice.
Zhang W; Deng J; Sunkara M; Morris AJ; Wang C; St Clair D; Vore M
J Pharmacol Exp Ther; 2015 Nov; 355(2):280-7. PubMed ID: 26354995
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
9. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury.
Neilan TG; Jassal DS; Perez-Sanz TM; Raher MJ; Pradhan AD; Buys ES; Ichinose F; Bayne DB; Halpern EF; Weyman AE; Derumeaux G; Bloch KD; Picard MH; Scherrer-Crosbie M
Eur Heart J; 2006 Aug; 27(15):1868-75. PubMed ID: 16717080
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective action of the aqueous extract of Terminalia arjuna bark against toxicity induced by doxorubicin.
Bishop S; Liu SJ
Phytomedicine; 2017 Dec; 36():210-216. PubMed ID: 29157817
[TBL] [Abstract][Full Text] [Related]
11. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity.
Akolkar G; Bhullar N; Bews H; Shaikh B; Premecz S; Bordun KA; Cheung DY; Goyal V; Sharma AK; Garber P; Singal PK; Jassal DS
Cardiovasc Ultrasound; 2015 Apr; 13():18. PubMed ID: 25889218
[TBL] [Abstract][Full Text] [Related]
12. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.
Hullin R; Métrich M; Sarre A; Basquin D; Maillard M; Regamey J; Martin D
Cardiovasc Res; 2018 Feb; 114(2):272-281. PubMed ID: 29016737
[TBL] [Abstract][Full Text] [Related]
13. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity.
Chicco AJ; Hydock DS; Schneider CM; Hayward R
J Appl Physiol (1985); 2006 Feb; 100(2):519-27. PubMed ID: 16210442
[TBL] [Abstract][Full Text] [Related]
14. The Ameliorative Effect of Pioglitazone against Neuroinflammation Caused by Doxorubicin in Rats.
Alsaud MM; Alhowail AH; Aldubayan MA; Almami IS
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375330
[TBL] [Abstract][Full Text] [Related]
15. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity.
Milano G; Biemmi V; Lazzarini E; Balbi C; Ciullo A; Bolis S; Ameri P; Di Silvestre D; Mauri P; Barile L; Vassalli G
Cardiovasc Res; 2020 Feb; 116(2):383-392. PubMed ID: 31098627
[TBL] [Abstract][Full Text] [Related]
16. Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Oronsky B; Ao-Ieong ESY; Yalcin O; Carter CA; Cabrales P
Mol Pharm; 2019 Jul; 16(7):2929-2934. PubMed ID: 31038318
[TBL] [Abstract][Full Text] [Related]
17. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice.
Shizukuda Y; Matoba S; Mian OY; Nguyen T; Hwang PM
Mol Cell Biochem; 2005 May; 273(1-2):25-32. PubMed ID: 16013437
[TBL] [Abstract][Full Text] [Related]
18. Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice.
Dolinsky VW; Rogan KJ; Sung MM; Zordoky BN; Haykowsky MJ; Young ME; Jones LW; Dyck JR
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E243-53. PubMed ID: 23695218
[TBL] [Abstract][Full Text] [Related]
19. Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications.
Xi L; Zhu SG; Das A; Chen Q; Durrant D; Hobbs DC; Lesnefsky EJ; Kukreja RC
Nitric Oxide; 2012 May; 26(4):274-84. PubMed ID: 22484629
[TBL] [Abstract][Full Text] [Related]
20. Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.
Yokoyama C; Aoyama T; Ido T; Kakino A; Shiraki T; Tanaka T; Nishigaki K; Hasegawa A; Fujita Y; Sawamura T; Minatoguchi S
PLoS One; 2016; 11(5):e0154994. PubMed ID: 27195769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
